International Assets Investment Management LLC Buys New Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

International Assets Investment Management LLC bought a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 17,186 shares of the company’s stock, valued at approximately $115,000.

Other hedge funds have also recently modified their holdings of the company. Citigroup Inc. grew its position in shares of GoodRx by 301.7% in the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock valued at $45,000 after buying an additional 6,006 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in shares of GoodRx in the 3rd quarter worth $68,000. Harbor Capital Advisors Inc. lifted its stake in shares of GoodRx by 22.7% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 14,995 shares of the company’s stock worth $84,000 after acquiring an additional 2,771 shares during the period. Victory Capital Management Inc. purchased a new stake in GoodRx during the third quarter worth about $121,000. Finally, Raymond James & Associates purchased a new stake in GoodRx during the fourth quarter worth about $192,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Price Performance

Shares of GDRX stock opened at $7.15 on Tuesday. The company has a market capitalization of $2.82 billion, a PE ratio of -357.32, a price-to-earnings-growth ratio of 3.94 and a beta of 1.42. The firm has a fifty day simple moving average of $6.95 and a 200-day simple moving average of $6.29. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.85. GoodRx Holdings, Inc. has a twelve month low of $4.14 and a twelve month high of $9.37.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Thursday, February 29th. The company reported $0.02 earnings per share for the quarter, meeting the consensus estimate of $0.02. GoodRx had a negative net margin of 1.18% and a positive return on equity of 2.45%. The business had revenue of $196.64 million during the quarter, compared to the consensus estimate of $195.59 million. Equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GDRX has been the subject of a number of research reports. Royal Bank of Canada lifted their target price on shares of GoodRx from $7.00 to $8.00 and gave the stock a “sector perform” rating in a research report on Friday, March 1st. Leerink Partnrs reaffirmed an “outperform” rating on shares of GoodRx in a research report on Monday, February 26th. JPMorgan Chase & Co. raised shares of GoodRx from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $7.00 to $10.00 in a research report on Friday, March 1st. UBS Group boosted their price objective on shares of GoodRx from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Friday, March 1st. Finally, Bank of America downgraded shares of GoodRx from a “buy” rating to an “underperform” rating and decreased their price objective for the stock from $8.00 to $4.50 in a research note on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, GoodRx presently has a consensus rating of “Hold” and a consensus target price of $8.78.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.